Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

John D. Shaughnessy, Jr., Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3389.

https://doi.org/10.1182/blood.V108.11.3389.3389

Published: 2006

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

S. Vincent Rajkumar, MD, Mohamad Hussein, John Catalano, Wieslaw Jedrzejcak, Svetlana Sirkovich, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerry Zeldis, Joan Blade

Blood (2006) 108 (11): 795.

https://doi.org/10.1182/blood.V108.11.795.795

Published: 2006

Journal Articles

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Anfan Wu, PhD, Alan List, MD, Richard Lush, MD, Kelly Bretz, BS, Robert Knight, MD, Jerry Zeldis, MD, Henry Lau, PhD

Blood (2006) 108 (11): 4854.

https://doi.org/10.1182/blood.V108.11.4854.4854

Published: 2006

Journal Articles

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Ashrof Z. Badros, MD, Olga Goloubeva, PhD, Bashi Ratterree, RN, Sabrina Natt, RN, Aaron Rapoport, MD, Javier Bolaños-Meade, MD, Ben Zhang, PhD, Jerry Zeldis, MD, PhD, Stanley Frankel, MD, Barry Meisenberg, MD, James Zwiebel, MD, J. Flaws, PhD, D. Tomic, PhD, Robert Fenton, MD, PhD

Blood (2004) 104 (11): 2400.

https://doi.org/10.1182/blood.V104.11.2400.2400

Published: 2004

NARROW

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only